Frequently Asked Questions about Hepion Pharmaceuticals, Inc. (HEPA)

Name: Hepion Pharmaceuticals, Inc. (HEPA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Hepion Pharmaceuticals, Inc. (HEPA) do?

Accepted Answer

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologi...

Question 2

Is Hepion Pharmaceuticals, Inc. (HEPA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of HEPA reveals an Altman Z-Score of -119.06 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if HEPA fits their risk profile.

Question 3

What is the current P/E ratio for HEPA?

Accepted Answer

As of the latest trading session, Hepion Pharmaceuticals, Inc. (HEPA) has a trailing P/E ratio of -0.06.

Question 4

Who is the CEO of Hepion Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of Hepion Pharmaceuticals, Inc. is Vincent LoPriore.

Question 5

What was HEPA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Hepion Pharmaceuticals, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does HEPA pay a dividend?

Accepted Answer

Hepion Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does HEPA have?

Accepted Answer

In its latest reporting period, Hepion Pharmaceuticals, Inc. generated $-0.00B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Hepion Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Hepion Pharmaceuticals, Inc. (HEPA) is currently 0.19.

Question 9

What is the Price-to-Sales (P/S) ratio of HEPA?

Accepted Answer

Based on trailing twelve-month data, Hepion Pharmaceuticals, Inc. (HEPA) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Hepion Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

Hepion Pharmaceuticals, Inc. (HEPA) has a Return on Equity (ROE) of -241.95%, representing its profitability relative to shareholder equity.

Period	Op. Income	Net Income	EPS
2025-12	-4.2M	-8.3M	-0.88
2024-12	-19.3M	-13.2M	-107.35
2023-12	-48.4M	-48.9M	-616.07
2022-12	-45.5M	-42.2M	-594.75
2021-12	-30.4M	-32.7M	-465.52

Period	Op. Income	Net Income	EPS
2025-12	-4.2M	-8.3M	-0.88
2024-12	-19.3M	-13.2M	-107.35
2023-12	-48.4M	-48.9M	-616.07
2022-12	-45.5M	-42.2M	-594.75
2021-12	-30.4M	-32.7M	-465.52